Background
==========

Colorectal cancer (CRC) is a common malignant disease around the world. CRC has an extremely poor prognosis owing to insidious symptomatology, late clinical presentation and rapid progression and so lead to poor 5-year disease-free survival \[[@B1],[@B2]\]. CRC is related not only to living habits such as dietary but also to the susceptibility of heredity \[[@B3]\]. Individuals who have first-degree relative with CRC have the increased risk of the CRC compared with those without a family history \[[@B4]\], suggesting that genetic factors contribute to risk for colorectal carcinogenesis \[[@B5]\].

The intercellular adhesion molecule-1 (ICAM-1) is a single-chain cell surface glycoprotein that belongs to the immunoglobulin superfamily. It is known that ICAM-1 can be aberrantly expressed in CRC and suppress cancer progression via activation of the host immune surveillance system and prevention of cells from detaching from the primary tumor mass and thus attenuate or eliminate metastasis \[[@B6],[@B7]\]. Two single-base polymorphisms in human ICAM-1 gene have been reported, in exon 4 and 6, changing codons 241(G241R) and 469(K469E), respectively, which are common genetic variations associated with diseases \[[@B8]\]. However, it is not well documented that the association of the ICAM-1 gene polymorphisms with CRC development. In present study, we analyze the association between the polymorphisms at exon 4 (G241R) and exon 6 (E469K) of *ICAM-1*and CRC susceptibility and in vivo differences in ICAM-1 level and differentiation in tumor tissues of patients with CRC. Our results suggest that tumor cell differentiation may be influenced by genetic variation in *ICAM-1*in Chinese population.

Materials and methods
=====================

Study population
----------------

87 cases were patients with a new diagnosis of colorectal adenocarcinoma attending a Hebei Medical University Forth Hospital, China between December 2007 and August 2008. 102 volunteers without CRC were used as controls. The average age of the subjects was 55 years (range, 34-83 years). The peripheral blood specimens from patients with CRC and controls were collected at the time of the diagnosis after informed consent was obtained. All the tumor and matched normal tissues investigated in this study were obtained from patients who had undergone a surgical resection. The diagnosis and staging of CRC were assessed according to the WHO classifications \[[@B9]\] and TMN classifications \[[@B10]\]. The study was approved by the institutional research board at Hebei Medical University.

Genotyping of ICAM-1 gene polymorphisms
---------------------------------------

Genomic DNA was extracted and purified from whole blood lymphocytes using a blood DNA Kit (Omega Bio-Tek Co., USA) according to the manufacturer\'s instructions. PCR with sequence-specific primers (SSP) was used to detect the *ICAM-1*polymorphisms at Exon 4 (G241R) and Exon 6 (E469K) as described elsewhere \[[@B11],[@B12]\]. For G241R in exon 4, two sequence-specific forward primers: 5\'-GTGGTCTGTTCCCTGGACG-3\'(G241) and 5\'-GTGGTCTGTTCCCTGGACA-3\' (R241), and for K469E (exon 6) two sequence-specific reverse primers: 5\'-GCACATTCACGGTCACCTC-3\' (K469) and 5\'-GCACATTCACGGTCACCTT-3\' (E469) were used. Each combination of the four primers contained one forward primer and one reverse primer for the 927 bp fragment of sequence-specific amplifications, respectively. For the positive internal control, the primers 5\'-GAAGGTGAAGGTCGGAGT-3\'(forward) and 5\'-GAAGATGGTGATGGGATTTC-3\' (reverse) coding for the 225 bp fragment of human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene were used.

PCR was performed in a final volume of 20 μl in 96-well plates. The final concentrations of the reagents were as follows: 200 μM of each dNTP, 2.5 mM MgCl~2~, 0.5 μM of each primer, polymerase buffer, between 0.01 and 0.1 mg DNA, and 0.2 units of Taq polymerase (Promaga). The PCR cycle conditions were 94°C for 4 min, followed by 35 cycles at 94°C for 30 s, 69°C for 45 s and 72°C for 40 s, with a final extension step at 72°C for 10 min. 927 bp of PCR product was identified by gel electrophoresis on 2% agarose gels stained with ethidium bromide.

ICAM-1 expression analysis
--------------------------

Western blot analysis was used to detect ICAM-1 protein expression in both tumor and matched adjacent normal tissues from patient with CRC as described previously \[[@B13]\]. The tissue lysates were prepared from the colorectal tissues \[[@B14]\]. Equal amounts of proteins were separated by electrophoresis on an 8% SDS-polyacrylamide gel and then electrophorytically transferred to polyvinylidene difluoride membranes (Millipore Co, Billerica, Massachusetts, USA). The membrane was incubated with anti-ICAM-1 antibody (1:1000; Santa Cruz), followed by a secondary anti-rabbit antibody (1:20000; Santa Cruz) using chemiluminescence protocol (Santa Cruz).

Immunohistochemistry analysis
-----------------------------

Immunostaining of sections from CRC tissues was performed with the anti-ICAM-1 (1:200) as described previously \[[@B15]\]. Staining intensities were determined by measuring the integrated optical density (IOD) with light microscopy using a computer-based Image-Pro Morphometric System by two independent observers in a double-blind manner.

Statistical analysis
--------------------

Each polymorphism was tested in controls to ensure the fitting with Hardy-Weinberg equilibrium. To test the hypothesis of association between genetic polymorphisms and CRC, multivariate methods based on logistic regression analyses were used. Allele and genotype frequencies in all subjects were calculated by direct counting. Hardy-Weinberg equilibrium was tested using the Fisher\'s exact test. The strength of the gene-cancer associations was measured by odds ratio (OR) and its 95% confidence interval (CI). *P*\< 0.05 was considered statistically significant. The SPSS was used in the statistical analysis.

Results
=======

Polymorphism of ICAM-1 K469 E may be associated with CRC risk
-------------------------------------------------------------

The polymorphisms of *ICAM-1*in all cases and controls are shown in Table [1](#T1){ref-type="table"}, which were conformed to Hardy-Weinberg equilibrium (*P*\> 0.05). In either CRC cases or controls, only GG genotype of *ICAM-1*exon 4 (G241R) was identified, while the exon 6 (K469E) homozygous and heterozygous individuals were observed (Figure [1](#F1){ref-type="fig"}). The distribution of the *ICAM-1*K469E genotypes was significantly different between CRC cases and controls (*P*\< 0.05). In 102 controls, the K allele frequency was 63.73%, which is different from that in the cancer cases (73.56%). Subjects with K allele in CRC had a 1.58-fold increase, compared with controls (*P*= 0.041). K allele was significantly associated with a increased risk of CRC (OR = 1.58, χ^2^= 4.194, 95% CI, 1.02\~2.46, *P*= 0.041). The frequency of KK genotype in CRC cases was more than that in the controls (57.47% vs 42.16%, χ^2^= 4.406, *P*= 0.036). Subjects with KK genotype had a 1.85-fold increase in CRC risk compared with those with KE+EE genotypes.

###### 

Allele and genotype frequencies of the ICAM-1 K469E polymorphisms in CRC cases and controls

  ------------------------------------------------------------------------------------------------
             **CRC (n = 87) (%)**   **Controls (n = 102) (%)**   ***P***    **OR (95% *CI*)**
  ---------- ---------------------- ---------------------------- ---------- ----------------------
  Genotype                                                                  

   KK        50 (57.47)             43 (42.16)                              

   KE        28 (32.18)             44 (43.14)                   0.036^a^   1.85 (1.04\~3.31)^b^

   EE        9 (10.35)              15 (14.7)                               

  Allele                                                                    

   K\        128 (73.56)\           130 (63.73)\                 0.041      1.58 (1.02\~2.46)^c^
  E          46 (26.44)             74 (36.27)                              
  ------------------------------------------------------------------------------------------------

OR, odds ratio; CI, confidence interval.

a, Genotypes: KK vs KE+EE.

b, OR for KK vs KE+EE genotypes in CRC.

c, OR for K vs E allele in CRC.

![***ICAM-1* G241R and K469E genotypes**. Lane M: Marker; Primers: G241-E469 (lane 1,5,9); G241-K469(lane 2,6,10); R241-E469(lane 3,7,11); R241-K469 (lane 4,8,12).](1756-9966-28-139-1){#F1}

Polymorphism of ICAM-1 K469E is associated with tumor differentiation
---------------------------------------------------------------------

The potential associations of the *ICAM-1*K469E genotype with tumor characteristics are presented in Table [2](#T2){ref-type="table"}. No correlation was found between K469E genotypes and tumor location, presence of lymph node metastases, Dukes stage, or age and gender at diagnosis. The KK genotype was more frequently found in cases with a well-differentiated CRC (*P*= 0.033) (Figure [2A](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}), although with the increased CRC risk. In contrast, the tumor tissues from the cases with KE+EE genotype showed poor differentiation compared with those with KK genotype (*P*\< 0.05). The results suggest that there is correlation between the K469E genotype and the phenotypical characteristics of CRC.

###### 

Distribution of various genotypes of ICAM-1 K469E in relation to clinicopathological and other variables in CRC cases

  **Variables**         **Cases (n)**   **KK**   **KE+EE**   ***χ*^2^**   ***P***
  --------------------- --------------- -------- ----------- ------------ ---------
  Age                                                                     
   ≤ 55                 27              16       11          0.051        0.821
   \> 55                60              34       26                       
  Gender                                                                  
   Male                 49              28       21          0.005        0.944
   Female               38              22       16                       
  Tumor location                                                          
   Colon                30              14       16          0.004        0.95
   Rectum               57              27       30                       
  Differentiation                                                         
  Well and moderately   62              33       29          4.564        0.033
  Poorly                25              7        18                       
  Metastasis                                                              
   No                   75              41       34          1.75         0.186
   Yes                  12              9        3                        
  Dukes stages                                                            
   A+B                  50              30       20          0.308        0.579
   C+D                  37              20       17                       

![**Polymorphism of *ICAM-1* K469E is associated with cancer differentiation and ICAM-1 expression in CRC**. (A), Representative histological sections of CRC with KK and EE genotypes (Magnification, × 400); (B), Western blot analysis for ICAM-1 expression of CRC with KK, KE and EE genotypes; (C), Densitometric scanning of Western blots, n = 15, \* *P*\< 0.05 vs controls; \# *P*\< 0.05 vs CRC with KK genotype; (D), Representative ICAM-1 staining of the cross sections of CRC with KK, KE and EE genotypes (Magnification, × 400); (E), Average IOD of ICAM-1 staining of CRC cross sections (n = 15). IOD represents relative ICAM-1 protein level in tumor tissues. \* *P*\< 0.05 vs KE+EE genotypes.](1756-9966-28-139-2){#F2}

KK genotype is correlated with increase in ICAM-1 expression in tumor tissues
-----------------------------------------------------------------------------

We next set out to assess whether the K469E genotype is correlated with differences in ICAM-1 expression using lysate extracted from the tumor and matched adjacent normal tissues of CRC patients with KK or KE+EE genotypes. There were no differences in ICAM-1 level in matched normal tissues of all tested patients. KK genotype patients showed an increase in the expression of ICAM-1 protein in tumor tissues relative to the matched normal tissues (*P*\< 0.05, Figure [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). However, the difference of ICAM-1 level between tumor and matched normal tissues was not observed in the patients with KE+EE genotypes. Meanwhile, ICAM-1 level was higher in the tumor tissues of individuals with KK genotype than that of the KE+EE genotypes (*P*\< 0.05). We also observed that the distribution of ICAM-1 was exclusively extracellular in all colorectal tumors (Figure [2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). Taken together, these results indicate that ICAM-1 protein is accumulated in CRC tissues with KK genotype.

Discussion
==========

Polymorphisms of *ICAM-1*K469E and G241R are common genetic variation in populations and associated with several autoimmune diseases, such as multiple sclerosis, type 1 diabetes, or Crohn\'s disease \[[@B12],[@B16],[@B17]\]. In current study, we have found only GG genotype individuals in either CRC cases or normal controls. The variants in G241R were not observed in our tested population, suggesting that the polymorphisms of G241R may be rare in Chinese, consistent with the Japanese and Koreans, respectively, probably reflecting that there is a common ancestor in these populations \[[@B16]\]. Our observation is different from the previous study concerning the G allele frequency in European-American population that showed less G allele frequency (0.796-0.971) \[[@B12],[@B18],[@B19]\]. The distribution of K469E genotypes and allele frequencies in exon 6 of the *ICAM-1*was significantly different between CRC patients and controls, and between patients with well differentiation and poor differentiation of tumor tissues. In CRC patients, the KK genotype was found more frequently than in the controls. The previous studies have shown that the K allele frequency is 0.437-0.630 in different populations \[[@B16],[@B20]\]. The KK genotype frequency in patients with well-differentiated tumor tissues was more than that in those of poor differentiation. Although the significance and the functional or therapeutic relevance of our findings remain to be elucidated, the most important finding is that the poor prognosis of CRC seems to be associated with allele E.

Although it is unclear how the *ICAM-1*K469E polymorphism contributes to the pathogenesis of CRC, we found that the increase in ICAM-1 expression was accompanied by well-differentiation in tumor tissues of KK genotype patients. ICAM-1, as a surface glycoprotein, is expressed on vascular endothelium, macrophages, and activated lymphocytes, and mediates leukocyte circulation and extravasation from the blood into the areas of inflammation and macrophage differentiation \[[@B21]-[@B23]\]. The epithelial cells of adult colon do not normally express ICAM-1 which can be expressed subsequent to malignant transformation \[[@B24],[@B25]\]. ICAM-1 expression decreases CRC metastasis and suppress cancer progression via promoting tumor cell motility and attachment to the extracellular matrix \[[@B6]\]. The previous study has showed that expression level of ICAM-1 is high in well differentiated tumor cells and low levels in poorly differentiated cells, and demonstrated a mechanism whereby ICAM-1 expression promotes CRC differentiation and retard metastasis \[[@B7]\]. ICAM-1 plays a role in promoting lymphocyte-mediated tumor killing \[[@B26]\], and this occurs as a result of enhanced binding of peripheral blood mononuclear cells to the tumor cells and subsequent tumor cell lysis \[[@B27]\]. Yet the study suggests that ICAM-1 enhances tumor cell attachment to the extracellular matrix by promoting motility in the context of remodeling, and appears to be acting as a morphogen \[[@B7]\]. These findings provide a possible reason why increasing of ICAM-1 expression occurs in well differentiated CRC tissues.

Conclusion
==========

Our study herein provides a potential genetic factor for the differentiation of CRC that correlates with *ICAM-1*K469E polymorphisms because of different ICAM-1 expression. However, we are unable to define the association of the *ICAM-1*K469E polymorphisms with CRC risk owing to the limitations of the size of the CRC and control populations in the present study. Our findings may help to evaluate the prognosis of CRC according to the individual genetic background.
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